Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies

Elizabeth A. Lippner, David B. Lewis, William H. Robinson*, Tamiko R. Katsumoto

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

The thymus is a key organ involved in establishing central immune tolerance. Thymic epithelial tumors (TETs) include thymomas and thymic carcinomas. Thymomas, which are histologically distinct from thymic carcinomas, lead to dysregulated thymopoiesis via decreased thymic epithelial expression of AIRE and MHC Class II, as well as via alterations in thymic architecture, thereby resulting in autoimmune complications that manifest as paraneoplastic disorders (PNDs). Although progress has been made in elucidating the mechanisms underlying thymoma-associated PNDs, there remains a great need to further define the underlying mechanisms and to identify additional immune biomarkers, such as novel antibodies (in “seronegative“ cases) to facilitate diagnosis and monitoring of patients. In addition, a better understanding of the pathogenesis of PNDs could lead to improved treatment strategies for both thymomas and their immune complications. In advanced, refractory cases of TETs (both thymoma and thymic carcinoma), additional therapeutic approaches are needed. Immune checkpoint inhibitors have revolutionized the treatment of several malignancies and hold promise in the treatment of TETs; however, the risks for immune-related adverse events (especially for inducing PNDs as well as in the setting of pre-existing PNDs) underscore the need to optimize patient selection and improve clinical management before there can be widespread acceptance of checkpoint inhibitor therapy in patients with TETs.

Original languageEnglish (US)
Article number62
JournalCurrent treatment options in oncology
Volume20
Issue number7
DOIs
StatePublished - Jul 1 2019
Externally publishedYes

Keywords

  • Autoimmune disease
  • Checkpoint inhibitor therapy
  • Good syndrome
  • Immunodeficiency
  • Immunotherapy
  • Myasthenia gravis
  • Paraneoplastic disease
  • Thymic carcinoma
  • Thymoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies'. Together they form a unique fingerprint.

Cite this